These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

217 related items for PubMed ID: 10855352

  • 1. [Gastrointestinal damage induced by celecoxib and rofecoxib in rats].
    Laudanno OM, Cesolari JA, Esnarriaga J, Rista L, Piombo G, Maglione C, Aramberry LJ, Sambrano JS, Godoy A, Rocaspana A.
    Acta Gastroenterol Latinoam; 2000; 30(1):27-33. PubMed ID: 10855352
    [Abstract] [Full Text] [Related]

  • 2. Gastrointestinal damage induced by celecoxib and rofecoxib in rats.
    Laudanno OM, Cesolari JA, Esnarriaga J, Rista L, Piombo G, Maglione C, Aramberry L, Sambrano J, Godoy A, Rocaspana A.
    Dig Dis Sci; 2001 Apr; 46(4):779-84. PubMed ID: 11330413
    [Abstract] [Full Text] [Related]

  • 3. [Celecoxib vs indomethacin and acute gastric lesions in rats].
    Laudanno OM, Esnarriaga JM, Cesolari JA, Maglione CB, Aramberry LJ, Sambrano JS, Piombo G, Rista L.
    Medicina (B Aires); 2000 Apr; 60(2):221-4. PubMed ID: 10962812
    [Abstract] [Full Text] [Related]

  • 4. Rofecoxib produces intestinal but not gastric damage in the presence of a low dose of indomethacin in rats.
    Yokota A, Taniguchi M, Takahira Y, Tanaka A, Takeuchi K.
    J Pharmacol Exp Ther; 2005 Jul; 314(1):302-9. PubMed ID: 15831440
    [Abstract] [Full Text] [Related]

  • 5. Ulcerogenic influence of selective cyclooxygenase-2 inhibitors in the rat stomach with adjuvant-induced arthritis.
    Kato S, Ogawa Y, Kanatsu K, Okayama M, Watanabe T, Arakawa T, Takeuchi K.
    J Pharmacol Exp Ther; 2002 Nov; 303(2):503-9. PubMed ID: 12388629
    [Abstract] [Full Text] [Related]

  • 6. Effect of nimesulide, rofecoxib and celecoxib on gastric tissue glutathione level in rats with indomethacin-induced gastric ulcerations.
    Altinkaynak K, Süleyman H, Akçay F.
    Pol J Pharmacol; 2003 Nov; 55(4):645-8. PubMed ID: 14581725
    [Abstract] [Full Text] [Related]

  • 7. Are rofecoxib and celecoxib safer NSAIDS?
    Drug Ther Bull; 2000 Nov; 38(11):81-6. PubMed ID: 11138599
    [Abstract] [Full Text] [Related]

  • 8. [Safety of specific cyclo-oxygenase 2 inhibitors].
    Lems WF, van de Laar MA, Bijlsma JW.
    Ned Tijdschr Geneeskd; 2001 Jun 02; 145(22):1044-7. PubMed ID: 11414163
    [Abstract] [Full Text] [Related]

  • 9. Roles of endogenous prostaglandins and cyclooxygenase izoenzymes in mucosal defense of inflamed rat stomach.
    Takeeda M, Hayashi Y, Yamato M, Murakami M, Takeuchi K.
    J Physiol Pharmacol; 2004 Mar 02; 55(1 Pt 2):193-205. PubMed ID: 15082878
    [Abstract] [Full Text] [Related]

  • 10. [Specific cyclo-oxygenase inhibitors. 2. Gastric toxicity?].
    Blondon H.
    Presse Med; 2000 Mar 11; 29(9):482-3. PubMed ID: 10745938
    [No Abstract] [Full Text] [Related]

  • 11. Relationship between selective cyclooxygenase-2 inhibitors and acute myocardial infarction in older adults.
    Solomon DH, Schneeweiss S, Glynn RJ, Kiyota Y, Levin R, Mogun H, Avorn J.
    Circulation; 2004 May 04; 109(17):2068-73. PubMed ID: 15096449
    [Abstract] [Full Text] [Related]

  • 12. Interactions between aspirin and COX-2 inhibitors or NSAIDs in a rat thrombosis model.
    Umar A, Boisseau M, Yusup A, Upur H, Bégaud B, Moore N.
    Fundam Clin Pharmacol; 2004 Oct 04; 18(5):559-63. PubMed ID: 15482377
    [Abstract] [Full Text] [Related]

  • 13. Effects of specific inhibition of cyclo-oxygenase-1 and cyclo-oxygenase-2 in the rat stomach with normal mucosa and after acid challenge.
    Gretzer B, Maricic N, Respondek M, Schuligoi R, Peskar BM.
    Br J Pharmacol; 2001 Apr 04; 132(7):1565-73. PubMed ID: 11264251
    [Abstract] [Full Text] [Related]

  • 14. The effects of some nonsteroidal anti-inflammatory drugs on experimental induced gastric ulcers in rats.
    Batu OS, Erol K.
    Inflammopharmacology; 2007 Dec 04; 15(6):260-5. PubMed ID: 18236017
    [Abstract] [Full Text] [Related]

  • 15. [Dexketoprofene, selective cox-1 inhibitor nsaids, without gastrointestinal injury in rats].
    Laudanno OM, Piombo G, Cesolari JA, Godoy A, Rocaspana A, Aramberry L.
    Acta Gastroenterol Latinoam; 2002 May 04; 32(1):17-20. PubMed ID: 12136686
    [Abstract] [Full Text] [Related]

  • 16. [Selective cyclooxygenase-2 inhibitors and the digestive tract].
    Chaabouni H, Amouri A, Cheikh I, Kchaou M, Ouerghi H, Ben Mami N, Ben Ammar A.
    Tunis Med; 2002 Aug 04; 80(8):427-33. PubMed ID: 12703120
    [Abstract] [Full Text] [Related]

  • 17. Comparison of antinociceptive efficacy and gastroprotection between celecoxib and diclofenac plus misoprostol in rats.
    Reyes-García G, Déciga-Campos M, Medina-Santillan R, Granados-Soto V.
    Proc West Pharmacol Soc; 2007 Aug 04; 50():69-71. PubMed ID: 18605234
    [Abstract] [Full Text] [Related]

  • 18. [A critical evaluation of side effect data on COX-2 inhibitors].
    Pomp E.
    Tidsskr Nor Laegeforen; 2002 Feb 20; 122(5):476-80. PubMed ID: 11961974
    [Abstract] [Full Text] [Related]

  • 19. Effect of (S)-4-(1-(5-chloro-2-(4-fluorophenyoxy)benzamido)ethyl) benzoic acid (CJ-42794), a selective antagonist of prostaglandin E receptor subtype 4, on ulcerogenic and healing responses in rat gastrointestinal mucosa.
    Takeuchi K, Tanaka A, Kato S, Aihara E, Amagase K.
    J Pharmacol Exp Ther; 2007 Sep 20; 322(3):903-12. PubMed ID: 17578900
    [Abstract] [Full Text] [Related]

  • 20. The cost effectiveness of rofecoxib and celecoxib in patients with osteoarthritis or rheumatoid arthritis.
    Maetzel A, Krahn M, Naglie G.
    Arthritis Rheum; 2003 Jun 15; 49(3):283-92. PubMed ID: 12794781
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 11.